

Cover Story
By Paul Goldberg and Tessa Vellek
Some of the questions that landed the AstraZeneca drug Olaparib (lynparza) before the FDA Oncologic Drugs Advisory Committee were classic:
By Tessa Vellek
In Brief
Trending Stories
- CBER Director Vinay Prasad sidelined staff to jettison Moderna’s mRNA flu shot
- The FY26 funding package gave NCI a raise, but the institute’s buying power is 18% less than it was two decades ago
Lowy: “We still have percentiles, but we’re not allowed to make awards exclusively on the basis of payline.” - Lou Weisbach tells us about his plan to raise $750 billion for the American Center for Cures
- Team USA’s Julie Letai competes in Milan Olympics speed skating event
- Richard Pazdur left FDA to avoid being part of “the destruction of the American medical system”
- Mail-out colorectal cancer screening programs extend, rather than replace, clinical care











